NSCLC Driven by DDR2 Mutation is Sensitive to JQ1 and Dasatinib Combination Therapy

ABSTRACT: Genetically engineered mouse models of lung cancer have demonstrated an important role in understanding the function of novel lung cancer oncogenes and tumor suppressor genes identified in genomic studies of human lung cancer. Further, these models are important platforms for pre-clinical therapeutic studies. Here, we generated a mouse model of lung adenocarcinoma driven by mutation of the Discoidin Domain Receptor 2 (DDR2) gene combined with loss of TP53. DDR2L63V;TP53L/L mice developed poorly differentiated lung adenocarcinomas in all transgenic animals analyzed with a latency of 40-50 weeks and a median survival of 67.5 weeks. Mice expressing wild-type DDR2 with combined TP53 loss did not form lung cancers. DDR2L63V; TP53L/L tumors displayed robust expression of DDR2 and immunohistochem

ORGANISM(S): Mus musculus

SUBMITTER: Chunxiao Xu 

PROVIDER: E-GEOD-64907 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress